Shopping Cart 0
Cart Subtotal
USD 0

Aurobindo Pharma Ltd (AUROPHARMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceutical company which develops, manufactures and exports formulations and active pharmaceutical ingredients (API's). Its products portfolio includes active pharma ingredients, formulations, antibiotics, anti-retrovirals, anti- allergics, gastroenterologicals, anti-Diabetics, HIVs, peptides, nutraceutical and aurozymes. It also offers contract research and manufacturing services across all the clinical stages of drug lifecycle. Aurobindo Pharma conducts research and development in the areas of product identification, literature evaluation, API process development, formulation development, pilot BA or BE, exhibiting batches for dossier submission, stability studies for global requirements, and dossier submission. The company has presence in China, South Africa, Australia, Germany, Japan, the US, the UK, and others. Aurobindo pharma is headquartered in Hyderabad, Telangana, India.

Aurobindo Pharma Ltd (AUROPHARMA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Aurobindo Pharma to Acquire Generics Business of Apotex 13

Novartis May Sell US Generic Pill Business 14

Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 16

Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 17

Aurobindo Pharma Denies Acquisition of Generic Drug Unit from Mallinckrodt 18

Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 19

Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 20

Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 21

Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 22

Partnerships 24

Aurobindo Pharma Forms Joint Venture with Tergene Biotech 24

Celon Labs Forms Joint Venture with Aurobindo Pharma 25

Licensing Agreements 26

Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 26

Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 28

Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 29

Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 30

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 31

Equity Offering 33

Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 33

Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 34

Asset Transactions 35

Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 35

Acquisition 36

Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 36

Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 37

Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 38

Aurobindo Pharma Acquires Natrol for USD132.5 Million 39

Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 40

Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 41

Aurobindo Pharma Ltd-Key Competitors 42

Aurobindo Pharma Ltd-Key Employees 43

Aurobindo Pharma Ltd-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Joint Venture 46

Recent Developments 47

Financial Announcements 47

May 28, 2018: Aurobindo Pharma Q4 FY17-18 and FY17-18 Financial Results 47

Nov 09, 2017: Aurobindo Pharma: Q2 FY17-18 Financial Results 49

Aug 09, 2017: Aurobindo Pharma: Consolidated Financial & Business Highlights-Q1FY18 51

Feb 09, 2017: Aurobindo Pharma Announces Q3 results & Limited Review Report for the Quarter ended December 31, 2016 52

Corporate Communications 53

Feb 09, 2017: Aurobindo Pharma Announces Change in Board of Directors 53

Legal and Regulatory 54

Mar 05, 2018: Aurobindo Pharma Issued Clarification on US FDA Observations 54

Mar 05, 2018: Aurobindo Announces Inspection of Unit 4 by US FDA 55

Mar 04, 2018: US inspectors cite serious quality issues at Aurobindo Pharma's Unit 4 56

Apr 19, 2017: Aurobindo Pharma Provides Update on US FDA Inspection at Bachupally Manufacturing Facility 57

Product News 58

May 13, 2018: Aurobindo Pharma's arm recalls 2 antibiotic injections from US 58

03/30/2017: Aurobindo Pharma receives USFDA Approval for Generic Epzicom tablets 59

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aurobindo Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aurobindo Pharma to Acquire Generics Business of Apotex 13

Novartis May Sell US Generic Pill Business 14

Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 16

Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 17

Aurobindo Pharma Denies Acquisition of Generic Drug Unit from Mallinckrodt 18

Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 19

Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 20

Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 21

Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 22

Aurobindo Pharma Forms Joint Venture with Tergene Biotech 24

Celon Labs Forms Joint Venture with Aurobindo Pharma 25

Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 26

Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 28

Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 29

Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 30

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 31

Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 33

Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 34

Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 35

Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 36

Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 37

Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 38

Aurobindo Pharma Acquires Natrol for USD132.5 Million 39

Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 40

Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 41

Aurobindo Pharma Ltd, Key Competitors 42

Aurobindo Pharma Ltd, Key Employees 43

Aurobindo Pharma Ltd, Other Locations 44

Aurobindo Pharma Ltd, Subsidiaries 44

Aurobindo Pharma Ltd, Joint Venture 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aurobindo Pharma Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceutical company which develops, manufactures and exports formulations and active pharmaceutical ingredients (API's). Its products portfolio includes active pharma ingredients, formulations, antibiotics, anti-retrovirals, anti- allergics, gastroenterologicals, anti-Diabetics, HIVs, peptides, nutraceutical and aurozymes. It also offers contract research and manufacturing services across all the clinical stages of drug lifecycle. Aurobindo Pharma conducts research and development in the areas of product identification, literature evaluation, API process development, formulation development, pilot BA or BE, exhibiting batches for dossier submission, stability studies for global requirements, and dossier submission. The company has presence in China, South Africa, Australia, Germany, Japan, the US, the UK, and others. Aurobindo pharma is headquartered in Hyderabad, Telangana, India.

Aurobindo Pharma Ltd (AUROPHARMA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Aurobindo Pharma to Acquire Generics Business of Apotex 13

Novartis May Sell US Generic Pill Business 14

Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 16

Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 17

Aurobindo Pharma Denies Acquisition of Generic Drug Unit from Mallinckrodt 18

Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 19

Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 20

Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 21

Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 22

Partnerships 24

Aurobindo Pharma Forms Joint Venture with Tergene Biotech 24

Celon Labs Forms Joint Venture with Aurobindo Pharma 25

Licensing Agreements 26

Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 26

Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 28

Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 29

Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 30

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 31

Equity Offering 33

Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 33

Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 34

Asset Transactions 35

Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 35

Acquisition 36

Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 36

Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 37

Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 38

Aurobindo Pharma Acquires Natrol for USD132.5 Million 39

Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 40

Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 41

Aurobindo Pharma Ltd-Key Competitors 42

Aurobindo Pharma Ltd-Key Employees 43

Aurobindo Pharma Ltd-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Joint Venture 46

Recent Developments 47

Financial Announcements 47

May 28, 2018: Aurobindo Pharma Q4 FY17-18 and FY17-18 Financial Results 47

Nov 09, 2017: Aurobindo Pharma: Q2 FY17-18 Financial Results 49

Aug 09, 2017: Aurobindo Pharma: Consolidated Financial & Business Highlights-Q1FY18 51

Feb 09, 2017: Aurobindo Pharma Announces Q3 results & Limited Review Report for the Quarter ended December 31, 2016 52

Corporate Communications 53

Feb 09, 2017: Aurobindo Pharma Announces Change in Board of Directors 53

Legal and Regulatory 54

Mar 05, 2018: Aurobindo Pharma Issued Clarification on US FDA Observations 54

Mar 05, 2018: Aurobindo Announces Inspection of Unit 4 by US FDA 55

Mar 04, 2018: US inspectors cite serious quality issues at Aurobindo Pharma's Unit 4 56

Apr 19, 2017: Aurobindo Pharma Provides Update on US FDA Inspection at Bachupally Manufacturing Facility 57

Product News 58

May 13, 2018: Aurobindo Pharma's arm recalls 2 antibiotic injections from US 58

03/30/2017: Aurobindo Pharma receives USFDA Approval for Generic Epzicom tablets 59

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aurobindo Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aurobindo Pharma to Acquire Generics Business of Apotex 13

Novartis May Sell US Generic Pill Business 14

Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 16

Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 17

Aurobindo Pharma Denies Acquisition of Generic Drug Unit from Mallinckrodt 18

Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 19

Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 20

Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 21

Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 22

Aurobindo Pharma Forms Joint Venture with Tergene Biotech 24

Celon Labs Forms Joint Venture with Aurobindo Pharma 25

Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 26

Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 28

Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 29

Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 30

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 31

Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 33

Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 34

Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 35

Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 36

Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 37

Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 38

Aurobindo Pharma Acquires Natrol for USD132.5 Million 39

Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 40

Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 41

Aurobindo Pharma Ltd, Key Competitors 42

Aurobindo Pharma Ltd, Key Employees 43

Aurobindo Pharma Ltd, Other Locations 44

Aurobindo Pharma Ltd, Subsidiaries 44

Aurobindo Pharma Ltd, Joint Venture 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aurobindo Pharma Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.